Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing 'STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Enzo Biochem posts 4Q profit NEW YORK (AP) _ Enzo Biochem Inc. (ENZ) on Thursday reported fiscal fourth-quarter earnings of $36.1 million. The New York-based company said it had profit of 77 cents per share. Losses, adjusted for non-recurring gains, came to 4 cents per share. The life sciences and biotechnology company posted revenue of $26.6 million in the period. For the year, the company reported net income of $45.3 million, or 97 cents per share, swinging to a profit in the period. Revenue was reported as $102.8 million. Enzo Biochem shares have risen 13 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $5.07, a rise of 34 percent in the last 12 months.
